Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rabies virus glycoprotein epitope I refers specifically to antigenic site I within residues 226–231 on the G protein's ectodomain. This region is highly exposed, functionally essential for viral entry, and represents a dominant target recognized by most potent anti-rabies monoclonal antibodies—making it crucial both as a marker for immune response evaluation and as a focus point in modern rabies vaccine design efforts.
Neutralizing antibodies binding to Epitope I can block viral entry by interfering with receptor binding or fusion processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rabies Virus Glycoprotein Epitope I (RABV-G Epitope I).